Elsamitrucin

N/A

Report date: 2024/01/16 10:56:30
NME

Base Information

Drug NameElsamitrucin
Drug Alias Name依沙芦星ElsamitrucineElsamitrucinaElsamicin AElsamitrucinum +[12] 
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionTopoisomerase II inhibitorsDNA topoisomerase I inhibitors
TargetsTopoisomerase IIDNA topoisomerase I
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Southern CaliforniaSpectrum Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG